Ascentage Pharma's Upcoming Investor Conferences
Ascentage Pharma Group International (NASDAQ: AAPG) is gearing up for a crucial month of December, where they are scheduled to present at three prominent investor conferences. This participation highlights their ongoing commitment to addressing cancer treatment through innovative solutions.
Key Conference Events
During these conferences, Ascentage Pharma’s leadership will discuss their groundbreaking research and therapies. Here’s a look at the events:
Piper Sandler 37th Annual Healthcare Conference
The Company will be represented at this notable conference with a fireside chat scheduled for 9:00 am EST on December 2nd. This is an excellent opportunity for investors to gain insights into their strategic direction and developments.
Evercore ISI HealthCONx Conference
On December 3rd, at 3:50 pm EST, Ascentage Pharma will hold another fireside chat during the Evercore ISI HealthCONx Conference. This platform allows the company to showcase their latest advancements and ongoing projects in the biopharmaceutical sector.
Citi 2025 Global Healthcare Conference
The following day, on December 4th, the company will participate in one-on-one meetings at the Citi 2025 Global Healthcare Conference, helping foster direct communication with potential investors and stakeholders.
About Ascentage Pharma Group International
Ascentage Pharma is a dynamic, integrated biopharmaceutical company dedicated to developing and commercializing unique therapies aimed at treating cancer. Through rigorous research, the company is tackling unmet medical needs with its pipeline filled with innovative drug candidates.
Innovative Pipeline and Products
A highlight of Ascentage Pharma's achievements includes its first approved product, Olverembatinib, recognized as a novel third-generation BCR-ABL1 inhibitor, currently benefiting patients in China with specific types of chronic myeloid leukaemia (CML). This comprehensive approach to treatment showcases the company's leadership in addressing the complexities of cancer.
Ascentage Pharma is further innovating with its second approved treatment, Lisaftoclax, which targets Bcl-2 for patients suffering from various hematologic malignancies. This product has gained traction in China and represents a leap in tackling previously challenging medical conditions.
Global Collaborations and Partnerships
To bolster its research and development efforts, Ascentage Pharma has established strategic partnerships with leading biotechnology and pharmaceutical firms, including Takeda, AstraZeneca, and Merck. These collaborations enhance their ability to innovate and expedite bringing therapies from conception to clinical use.
Future Outlook
The company’s roadmap includes pivotal Phase III trials for its products, ensuring that they continue to advance and refine their therapies based on clinical outcomes. As they endeavor to expand their influence within the pharmaceutical landscape, investor interest will likely drive forward their already impressive initiatives.
Contact Information
For more inquiries about their research and upcoming events, investors may connect with Ascentage Pharma’s Investor Relations team. Stella Yang can be reached at Stella.Yang@ascentage.com or by phone at +1 (301) 792-6286. Additional inquiries about media relations can be directed to Sean Leous at AscentagePR@icrhealthcare.com.
Frequently Asked Questions
What events will Ascentage Pharma participate in December?
Ascentage Pharma will participate in the Piper Sandler Annual Healthcare Conference, Evercore ISI HealthCONx Conference, and Citi 2025 Global Healthcare Conference.
What is the focus of Ascentage Pharma?
The company aims to discover, develop, and commercialize novel therapies for cancer treatment, addressing unmet medical needs.
What products does Ascentage Pharma currently offer?
Ascentage Pharma offers several innovative treatments including Olverembatinib and Lisaftoclax, both targeting specific cancer conditions.
Who can I contact for investor relations at Ascentage Pharma?
Investors can reach Stella Yang at Stella.Yang@ascentage.com for inquiries.
How does Ascentage Pharma support its research?
Ascentage Pharma collaborates with leading pharmaceutical companies and research institutions to enhance its research and development efforts.